

BDR Pharma unveils prostate cancer drug BDENZA in 160 mg capacity

28 February 2022 | News

Patients will have one tablet to ensure better efficacy



BDR Pharmaceuticals has launched BDENZA in 160 mg strength aiding the convenience of prostate cancer patients. The medicine was previously available in 40 mg and 80 mg strength for which patients had to consume 2 tablets a day as per approved dosage is primarily used to treat prostate cancer patients.

The objective behind the launch of Enzalutamide 160mg is to ensure better efficacy, minimum side effects, contain relapse cases by blocking the hormones of cancer cells providing an evolved treatment.

Patients will now have to consume only one tablet a day making it patient compliant, thereby reducing the associated stress of an already stressed out cancer patient.

Raheel Shah, Director Business Development from BDR Pharmaceuticals Int'l, Mumbai said, "Our focused launch of such expanded brand strength will definitely add value to Indian Oncology patients as well as provide opportunity for Medical Physicians to comply with patient outcome and standard treatment protocol. This represents firm commitment to providing access to affordable medicines for Indian cancer patients with high a quality standard".